Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 151

1.

Prognostic implications of the NIH consensus criteria in children with chronic graft-versus-host disease.

Lee JW, Lee DH, Jang PS, Yi MS, Chung NG, Cho B, Jeong DC, Kim HK.

Yonsei Med J. 2011 Sep;52(5):779-86. doi: 10.3349/ymj.2011.52.5.779.

2.

Validation of National Institutes of Health global scoring system for chronic graft-versus-host disease (GVHD) according to overall and GVHD-specific survival.

Moon JH, Sohn SK, Lambie A, Ellis L, Hamad N, Uhm J, Gupta V, Lipton JH, Messner HA, Kuruvilla J, Kim D.

Biol Blood Marrow Transplant. 2014 Apr;20(4):556-63. doi: 10.1016/j.bbmt.2014.01.010. Epub 2014 Jan 18.

3.

Feasibility of NIH consensus criteria for chronic graft-versus-host disease.

Cho BS, Min CK, Eom KS, Kim YJ, Kim HJ, Lee S, Cho SG, Kim DW, Lee JW, Min WS, Kim CC.

Leukemia. 2009 Jan;23(1):78-84. doi: 10.1038/leu.2008.276. Epub 2008 Oct 2.

PMID:
18830253
4.

Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome.

Weisdorf D, Haake R, Blazar B, Miller W, McGlave P, Ramsay N, Kersey J, Filipovich A.

Blood. 1990 Feb 15;75(4):1024-30.

5.

Validation of NIH consensus criteria for diagnosis and severity-grading of chronic graft-versus-host disease.

Aisa Y, Mori T, Kato J, Yamane A, Kohashi S, Kikuchi T, Okamoto S.

Int J Hematol. 2013 Feb;97(2):263-71. doi: 10.1007/s12185-013-1268-1. Epub 2013 Feb 1.

PMID:
23371545
6.

Incidence and outcome of chronic graft-versus-host disease using National Institutes of Health consensus criteria.

Jagasia M, Giglia J, Chinratanalab W, Dixon S, Chen H, Frangoul H, Engelhardt B, Goodman S, Greer J, Kassim A, Morgan D, Ruffner K, Schuening F.

Biol Blood Marrow Transplant. 2007 Oct;13(10):1207-15. Epub 2007 Aug 24.

7.

The global severity of chronic graft-versus-host disease, determined by National Institutes of Health consensus criteria, is associated with overall survival and non-relapse mortality.

Pidala J, Kim J, Anasetti C, Nishihori T, Betts B, Field T, Perkins J.

Haematologica. 2011 Nov;96(11):1678-84. doi: 10.3324/haematol.2011.049841. Epub 2011 Jul 26.

8.

Peripheral blood versus bone marrow as a source of hematopoietic stem cells for allogeneic transplantation in children with class I and II beta thalassemia major.

Ghavamzadeh A, Iravani M, Ashouri A, Mousavi SA, Mahdavi N, Shamshiri A, Hadjibabaie M, Namdar R, Nedaeifard L, Ghaffari H, Alimoghaddam K.

Biol Blood Marrow Transplant. 2008 Mar;14(3):301-8. doi: 10.1016/j.bbmt.2007.12.491.

9.

Response and survival of patients with chronic graft-versus-host disease treated by extracorporeal photochemotherapy: a retrospective study according to classical and National Institutes of Health classifications.

Del Fante C, Scudeller L, Viarengo G, Bernasconi P, Perotti C.

Transfusion. 2012 Sep;52(9):2007-15. doi: 10.1111/j.1537-2995.2011.03542.x. Epub 2012 Feb 10.

PMID:
22320219
10.

Prognostic factors of chronic graft-versus-host disease following allogeneic peripheral blood stem cell transplantation: the national institutes health scale plus the type of onset can predict survival rates and the duration of immunosuppressive therapy.

Pérez-Simón JA, Encinas C, Silva F, Arcos MJ, Díez-Campelo M, Sánchez-Guijo FM, Colado E, Martín J, Vazquez L, del Cañizo C, Caballero D, San Miguel J.

Biol Blood Marrow Transplant. 2008 Oct;14(10):1163-71. doi: 10.1016/j.bbmt.2008.07.015.

11.

A comparison of related donor peripheral blood and bone marrow transplants: importance of late-onset chronic graft-versus-host disease and infections.

Anderson D, DeFor T, Burns L, McGlave P, Miller J, Wagner J, Weisdorf D.

Biol Blood Marrow Transplant. 2003 Jan;9(1):52-9.

12.

Chronic graft-versus-host disease after allogeneic bone marrow transplantation from an unrelated donor: incidence, risk factors and association with relapse. A report from the Japan Marrow Donor Program.

Ozawa S, Nakaseko C, Nishimura M, Maruta A, Cho R, Ohwada C, Sakamaki H, Sao H, Mori S, Okamoto S, Miyamura K, Kato S, Kawase T, Morishima Y, Kodera Y; Japan Marrow Donor Program.

Br J Haematol. 2007 Apr;137(2):142-51.

PMID:
17391494
13.

The graft-versus-leukemia effect is mainly restricted to NIH-defined chronic graft-versus-host disease after reduced intensity conditioning before allogeneic stem cell transplantation.

Thepot S, Zhou J, Perrot A, Robin M, Xhaard A, de Latour RP, Ades L, Ribaud P, Petropoulou AD, Porcher R, Socié G.

Leukemia. 2010 Nov;24(11):1852-8. doi: 10.1038/leu.2010.187. Epub 2010 Sep 9.

PMID:
20827288
14.
15.

Comparative analysis of clinical outcomes after allogeneic bone marrow transplantation versus peripheral blood stem cell transplantation from a related donor in Japanese patients.

Tanimoto TE, Yamaguchi T, Tanaka Y, Saito A, Tajima K, Karasuno T, Kasai M, Kishi K, Mori T, Maseki N, Morishima S, Miyakoshi S, Kasai M, Ohno Y, Kim SW, Numata A, Kami M, Takaue Y, Mori S, Harada M.

Br J Haematol. 2004 May;125(4):480-93.

PMID:
15142119
16.
17.

Increase of interleukin-18 serum levels after engraftment correlates with acute graft-versus-host disease in allogeneic peripheral blood stem cell transplantation.

Scholl S, Sayer HG, Mügge LO, Kasper C, Pietraszczyk M, Kliche KO, Clement JH, Höffken K.

J Cancer Res Clin Oncol. 2004 Dec;130(12):704-10. Epub 2004 Sep 7.

PMID:
15365821
18.

Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD.

Vigorito AC, Campregher PV, Storer BE, Carpenter PA, Moravec CK, Kiem HP, Fero ML, Warren EH, Lee SJ, Appelbaum FR, Martin PJ, Flowers ME; National Institutes of Health.

Blood. 2009 Jul 16;114(3):702-8. doi: 10.1182/blood-2009-03-208983. Epub 2009 May 21.

19.

Clinical significance of subcategory and severity of chronic graft-versus-host disease evaluated by National Institutes of Health consensus criteria.

Sato T, Ichinohe T, Kanda J, Yamashita K, Kondo T, Ishikawa T, Uchiyama T, Takaori-Kondo A.

Int J Hematol. 2011 Apr;93(4):532-41. doi: 10.1007/s12185-011-0820-0. Epub 2011 Apr 5.

PMID:
21465116
20.

Early treatment of acute graft-versus-host disease with high- or low-dose 6-methylprednisolone: a multicenter randomized trial from the Italian Group for Bone Marrow Transplantation.

Van Lint MT, Uderzo C, Locasciulli A, Majolino I, Scimé R, Locatelli F, Giorgiani G, Arcese W, Iori AP, Falda M, Bosi A, Miniero R, Alessandrino P, Dini G, Rotoli B, Bacigalupo A.

Blood. 1998 Oct 1;92(7):2288-93.

Supplemental Content

Support Center